Small Pharma: KOL Roundtable on Short-duration Psychedelic Treatments for Depression
About The Event
A Key Opinion Leader Roundtable with Jerry Rosenbaum, MD, Harvard Medical School, and David Erritzoe, MD, PhD, Imperial College London
Small Pharma’s Chief Medical & Scientific Officer, Dr. Carol Routledge, will facilitate a roundtable discussion between psychiatrists, Dr. Rosenbaum and Dr. Erritzoe, on key topics surrounding the opportunity for short-duration psychedelic treatments.
Dr. Rosenbaum and Dr. Erritzoe will offer their expert opinions on the treatment toolkit available to psychiatrists today, and what it would take to deliver new psychedelic-based treatments for patients living with depression.
The discussion will highlight Small Pharma’s recent positive Phase IIa results for its lead candidate, SPL026 with supportive therapy, for the treatment of Major Depressive Disorder. SPL026 is Small Pharma’s proprietary synthetic formulation of N,N, dimethyltryptamine (DMT), which offers an ultra-short psychedelic experience of 20-25 minutes.
The SPL026 Phase IIa trial was the first placebo-controlled study to demonstrate efficacy of a short-duration psychedelic with therapy in treating depression.
A live Q&A session will follow the roundtable discussion.